Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma.
Pancreatic cancer (PC) is a leading cause of cancer death worldwide, especially in Western societies. Its aggressive nature and poor prognosis increase the need for identifying new and more accurate diagnostic and prognostic tools. We studied 41 patients who had undergone radical surgical resection for PC, investigated B7H4 protein expression in the PC tissue specimens of these patients by immunohistochemistry and analyzed several clinical and pathological features. The positive expression of the B7H4 antigen was associated with a negative impact of chemotherapy with gemcitabine on patient survival and also correlated with high CA19.9 serum levels and poorly differentiated tumors. Moreover, patients that overexpressed B7H4 antigen had worse prognosis compared to the ones that did not overexpress B7H4. B7H4 antigen is a negative prognostic marker for PC patients and also seems to express resistance of PC patients to chemotherapy with gemcitabine.
2nd Department of Surgery and Laboratory of Experimental Surgery, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. natasha_tsia@yahoo.com.|Department of Surgery, General Hospital 'Agios Dimitrios', Thessaloniki, Greece. natasha_tsia@yahoo.com.
Anastasia
http://orcid.org/0000-0002-1083-766X
A
Tsiaousidou
2nd Department of Surgery and Laboratory of Experimental Surgery, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
A K
AK
Tsaroucha
Laboratory of Histology, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
M
M
Lambropoulou
2nd Department of Surgery and Laboratory of Experimental Surgery, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
M
M
Pitiakoudis
1st Department of Surgery, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
A
A
Polychronidis
Department of Surgery, General Hospital 'Agios Dimitrios', Thessaloniki, Greece.
E
E
Chatzitheoklitos
2nd Department of Surgery and Laboratory of Experimental Surgery, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
K
K
Romanidis
2nd Department of Surgery and Laboratory of Experimental Surgery, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
C
C
Simopoulos
D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D044967:Serum / Q000737:chemistry*; D016019:Survival Analysis; D016896:Treatment Outcome; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1 / Q000032:analysis*; D000093542:Gemcitabine
D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1; D003841:Deoxycytidine; D000093542:Gemcitabine
B7H4; Biomarkers; Chemotherapy resistance; Immunohistochemistry; Pancreatic cancer